AMRIZOLE 1000 MG (METRONIDAZOLE) – RECTAL SUPPOSITORIES

Active Ingredient: Metronidazole 1000 mg
Pharmaceutical Form: Rectal suppositories
Pack Size: 5 suppositories
Therapeutic Class: Nitroimidazole antimicrobial agent (Antibacterial and Antiprotozoal).

Product Overview

Amrizole 1000 mg contains metronidazole, a nitroimidazole antimicrobial agent with activity against susceptible anaerobic bacteria and certain protozoa.

Metronidazole works by entering susceptible microorganisms and forming active compounds that damage their DNA, inhibit nucleic acid synthesis, and ultimately lead to microbial cell death.

The rectal suppository formulation provides an alternative route of administration when prescribed by a healthcare professional, particularly when oral administration is unsuitable.

Indications and Uses

Amrizole 1000 mg may be prescribed for the treatment or prevention of infections caused by susceptible anaerobic bacteria, particularly when rectal administration is required.

Potential clinical uses include:

• Anaerobic bacterial infections: Treatment of infections caused by susceptible anaerobic organisms, including Bacteroides, Clostridium, and anaerobic streptococci.
• Intra-abdominal infections: As part of an appropriate antimicrobial treatment regimen.
• Postoperative infections: Prevention or treatment of anaerobic infections associated with abdominal and colorectal surgery.
• Pelvic and gynecological infections: When anaerobic bacterial coverage is clinically indicated.
• Certain severe infections: As an alternative route of administration when oral medication cannot be given.

The Egyptian Drug Authority's National Formulary recognizes the 1 g rectal suppository formulation of metronidazole and lists its use in anaerobic infections and surgical prophylaxis.

Mechanism of Action

Metronidazole enters susceptible anaerobic microorganisms, where its nitro group is reduced to form active compounds.

These compounds:

• Damage microbial DNA.
• Inhibit nucleic acid synthesis.
• Interfere with essential cellular functions.
• Ultimately cause the death of susceptible microorganisms.

Dosage and Administration

Route of Administration: Rectal only.

• Remove the suppository from its packaging before use.
• Insert gently into the rectum (anus).
• Wash hands before and after administration.
• Follow the prescribed treatment schedule.

Typical adult dosing for certain anaerobic infections:

• A commonly referenced regimen for 1 g metronidazole suppositories is one suppository every 8 hours.
• If rectal treatment continues beyond 3 days, some product guidelines recommend reducing the frequency to every 12 hours.
• Oral treatment should replace rectal administration as soon as the patient can take medication by mouth, when clinically appropriate.

►Important: These are reference regimens, not individualized instructions. The actual dose and duration must be determined by the treating physician.

Possible Side Effects

Possible adverse effects include:

• Nausea and vomiting.
• Diarrhea.
• Abdominal discomfort.
• Metallic or unpleasant taste.
• Headache and dizziness.
• Rectal irritation or discomfort.
• Dark-colored urine.

Rare but serious adverse reactions may include:

• Allergic reactions.
• Peripheral neuropathy (numbness or tingling).
• Seizures.
• Confusion or other neurological disturbances.
• Severe skin reactions.

Seek medical attention if serious or unusual symptoms develop.

Contraindications and Precautions

Contraindications:

• Known hypersensitivity to metronidazole or other nitroimidazole derivatives.
• Recent disulfiram use (within the previous two weeks).

Precautions:

• Use cautiously in patients with severe liver impairment.
• Patients with neurological disorders should be carefully monitored.
• Patients with blood disorders should inform their healthcare professional before treatment.
• Use during pregnancy or breastfeeding requires medical assessment.
• Patients taking warfarin or other anticoagulants may require additional monitoring.
• Inform the doctor about all medications being used.

Important Drug and Lifestyle Interactions

• Alcohol: Avoid alcoholic beverages during treatment and for at least 48 hours after the last dose, following applicable product guidance.
• Disulfiram: Concurrent use may cause serious psychiatric reactions.
• Warfarin: Metronidazole may increase anticoagulant effects and bleeding risk.
• Lithium: May increase lithium concentrations and the risk of toxicity.

Storage Conditions

• Store according to the manufacturer's recommended temperature.
• Protect from excessive heat and direct sunlight.
• Keep in the original packaging.
• Keep out of reach of children.
• Do not use after the expiry date.

Patient Counseling Points

• Amrizole suppositories are intended for rectal administration only.
• Do not swallow or insert vaginally.
• Follow the prescribed dosage and treatment duration.
• Avoid alcohol during treatment.
• Do not discontinue treatment without consulting your doctor.
• Report persistent symptoms or unusual neurological reactions to your healthcare professional.

Medical References

1. Egyptian Drug Authority (EDA): Egyptian National Formulary – Antimicrobials, Metronidazole. View official formulary.
2. Health Products Regulatory Authority (HPRA): Flagyl Suppositories – Summary of Product Characteristics. View prescribing information.
3. UK Medicines and Healthcare products Regulatory Agency (MHRA): Metronidazole suppository product information. View product information.
4. NHS: How and when to take or use metronidazole. Read patient guidance.

Patient Disclaimer: This information is intended for educational purposes only and should not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before using this medication. The appropriate dosage and duration depend on the type and severity of infection and the patient's individual medical condition.